Baschnagel Andrew M, Wobb Jessica L, Dilworth Joshua T, Williams Lindsay, Eskandari Mohammad, Wu Dafang, Pruetz Barbara L, Wilson George D
Department of Human Oncology, University of Wisconsin, Madison, USA.
Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, USA.
Radiother Oncol. 2015 Oct;117(1):118-24. doi: 10.1016/j.radonc.2015.08.025. Epub 2015 Aug 29.
To investigate the relationship between FDG-PET maximum standard uptake value (SUVmax), p16, EGFR, GLUT1 and HK2 expression in head and neck squamous cell carcinomas (HNSCC).
Immunohistochemical staining of p16, EGFR, GLUT1 and HK2 was performed on primary tumor tissue from 97 locally advanced HNSCC patients treated with definitive chemoradiation. SUVmax along with p16, EGFR, GLUT1 and HK2 expression were analyzed for associations including local control, locoregional control and disease free survival.
Pretreatment SUVmax in primary tumors did not differ when stratified by p16, EGFR or GLUT1 expression but SUVmax was significantly higher in HK2 expressing tumors (p=0.021) and in tumors with higher T-stage (p=0.022). GLUT1 expression was significantly higher in p16 negative (p<0.001) and EGFR positive tumors (p<0.01). HK2 expressing tumors were associated with EGFR positive tumors (p=0.022) but not with p16 or GLUT1 expression. EGFR positive, p16 negative and high GLUT1 expressing tumors were associated with worse local control and disease free survival on univariate analyses. After adjusting for patient and treatment characteristics p16 status was the only factor that predicted for outcome on multivariate analysis.
High GLUT1 expression was associated with EGFR positive and p16 negative HNSCC tumors. GLUT1 maybe an important biomarker in HNSCC but its expression appears dependent on p16 status.
探讨氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)最大标准摄取值(SUVmax)与头颈部鳞状细胞癌(HNSCC)中p16、表皮生长因子受体(EGFR)、葡萄糖转运蛋白1(GLUT1)和己糖激酶2(HK2)表达之间的关系。
对97例接受根治性放化疗的局部晚期HNSCC患者的原发肿瘤组织进行p16、EGFR、GLUT1和HK2的免疫组织化学染色。分析SUVmax以及p16、EGFR、GLUT1和HK2表达与局部控制、区域控制和无病生存期之间的相关性。
按p16、EGFR或GLUT1表达分层时,原发肿瘤的治疗前SUVmax无差异,但HK2表达阳性的肿瘤中SUVmax显著更高(p = 0.021),且在T分期较高的肿瘤中也显著更高(p = 0.022)。在p16阴性(p < 0.001)和EGFR阳性的肿瘤中GLUT1表达显著更高(p < 0.01)。HK2表达阳性的肿瘤与EGFR阳性的肿瘤相关(p = 0.022),但与p16或GLUT1表达无关。单因素分析显示,EGFR阳性、p16阴性和GLUT1高表达的肿瘤与较差的局部控制和无病生存期相关。在调整患者和治疗特征后,多因素分析显示p16状态是唯一预测预后的因素。
GLUT1高表达与EGFR阳性和p16阴性的HNSCC肿瘤相关。GLUT1可能是HNSCC中的一个重要生物标志物,但其表达似乎依赖于p16状态。